Stay updated with breaking news from Maia kayal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts review best practices around plan design that payers and plan sponsors should address as more interchangeable biosimilars potentially enter the market. ....
Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy. ....
Maia Kayal, MD, MS, defines interchangeability and reviews the requirements from the FDA, "switching studies," and meaningful difference verses class effect. ....
David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options. ....